View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 3, 2021updated 11 Jul 2022 2:19pm

Ionis begins clinical trial of severe hypertriglyceridemia medicine

Olezarsen hinders the apoC-III production for patients at risk for cardiometabolic disease and acute pancreatitis.

Ionis Pharmaceuticals has commenced the Phase III CORE clinical trial of investigational antisense medicine, olezarsen, in patients with severe hypertriglyceridemia.

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

Formerly called IONIS-APOCIII-LRx, Olezarsen uses Ionis’ LIgand-Conjugated Antisense technology and hinders the apoC-III production for patients at risk of cardiometabolic disease and acute pancreatitis due to an increase in triglyceride levels.

Ionis Pharmaceuticals clinical development senior vice-president and cardiovascular franchise leader Sotirios Tsimikas said: “Severe hypertriglyceridemia is a common condition that affects millions of people around the world, including more than three million in the US.

“Initiating the CORE study is a major step in realising the full potential of olezarsen to treat the range of conditions related to elevated triglycerides associated with high levels of the apoC-llI protein.”

The global, randomised, double-blind, registrational, and placebo-controlled Phase III study will assess the efficacy of olezarsen compared to placebo in patients with triglyceride levels greater than or equal to 500mg/dL.

In this trial, approximately 450 participants will be randomised and given olezarsen or placebo in a treatment period for 53 weeks.

The percentage change from baseline in fasting triglycerides at month six is the trial’s primary endpoint.

Meanwhile, the secondary goals include the per cent change in fasting triglycerides from baseline at 12 months and other atherogenic lipids from baseline at six and 12 months.

Adjudicated acute pancreatitis event rates during the treatment period, as well as the proportion of patients who achieve fasting triglycerides that are less than 500 mg/dL, 880mg/dL and/or 1,000mg/dL will also form the secondary endpoints of the trial.

The company stated that the medicine has met both the endpoints with significant reductions in the levels of apoC-III and triglyceride in a Phase II clinical trial.

Additionally, olezarsen showed a favourable tolerability and safety profile in patients’ treatment with hypertriglyceridemia (≥200mg/dL to ≤500mg/dL) who have cardiovascular disease or are at risk for it.

Severe hypertriglyceridemia is associated with high ApoC-III and chylomicronemia levels, which lead to a higher risk of cardiovascular disease.

Related Companies

Free Case Study
img

Direct-to-Patient Trials: How IRT Plays an Important Role in Bellerophon's Direct-to-Patient Trials

As the industry strengthens its focus on patient centricity, Direct-to-Patient clinical trials have emerged as a popular trial design that have the potential to increase patient recruitment and retention. IRT plays a crucial role in the success of a Direct-to-Patient trial. Because drug supplies are being managed and shipped from distribution facilities directly to patients’ homes, a sponsor must have a high-quality system in place to accurately track the chain of custody, ensure patient-blinding and handle other logistical challenges. What You Will Learn Benefits and challenges associated with the Direct-to-Patient model Bellerophon's top considerations when implementing this trial design How IRT can equip study teams to successfully track chain of custody, ensure patient blinding, and handle logistical challenges
by Suvoda
Enter your details here to receive your free Case Study.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena